GeneDx Holdings Corp

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Keynote session to highlight value of GeneDx genomic data and clinical insights to accelerate genetic neurodevelopmental disorder pipeline for Mahzi Therapeutics Keynote session to highlight value of GeneDx genomic data and clinical insights to accelerate genetic neurodevelopmental disorder pipeline for Mahzi Therapeutics

GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations

STAMFORD, Conn., May 22, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it had received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that, because the Company's Class A common stock had a closing bid price at or above $1.00 per share for a minimum of ten (10) consecutive business days, the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450(a)(1), and that the matter is now closed.

GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement

GeneDx Holdings Corp. (WGS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -27.82% in 4 Weeks, Here's Why You Should You Buy the Dip in GeneDx Holdings Corp. (WGS)

GeneDx Holdings Corp. (NASDAQ:WGS ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 AM ET Company Participants Tricia Truehart - Head Investor Relations Katherine Stueland - President & Chief Executive Office Kevin Feeley - Chief Financial Officer Conference Call Participants Brandon Couillard - Jefferies Operator Good day and thank you for standing by. Welcome to the GeneDx' First Quarter 2023 Conference Call.

GeneDx Holdings Corp. (WGS) Q1 2023 Earnings Call Transcript

New Option Enables Easier DNA Sample Collection from Biological Parents to Aid in Disease Diagnosis New Option Enables Easier DNA Sample Collection from Biological Parents to Aid in Disease Diagnosis

GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option

STAMFORD, Conn., May 03, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced a clarification regarding the CUSIP number for the Company's public warrants. As previously disclosed on April 28, 2023, the Company will effect a 1-for-33 reverse split of Class A common stock, which will open for trading on the Nasdaq Global Select Market on Thursday, May 4, 2023 on a split-adjusted basis under the current trading symbol “WGS”. The CUSIP number for the Company's public warrants will stay the same as the previous CUSIP number, 81663L 119.

GeneDx Announces Clarification Regarding CUSIP Number for Public Warrant Holders

The genetic-testing specialist is effecting a reverse stock split. Although fully expected, this still wasn't encouraging news for shareholders.

Why GeneDx Holdings Stock Lagged the Market Today

STAMFORD, Conn., April 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that its board of directors has approved a 1-for-33 reverse stock split of the Company's Class A common stock. The Class A common stock will open for trading on the Nasdaq Global Select Market on Thursday, May 4, 2023 on a split-adjusted basis under the current trading symbol “WGS”. In connection with the reverse stock split, the CUSIP numbers for the Company's Class A common stock will change to 81663L 200 and for the Company's public warrants to 81663L 127. The reverse stock split is intended to enable GeneDx to regain compliance with the minimum bid price required for continued listing on the Nasdaq Global Select Market. The reverse stock split was approved by GeneDx's stockholders on April 14, 2023, with the final ratio determined by the Company's board of directors on April 24, 2023.

GeneDx Announces Reverse Stock Split

STAMFORD, Conn., April 18, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the first quarter of 2023 after the market closes on Tuesday, May 9, 2023. On the same day, Katherine Stueland, President and Chief Executive Officer and Kevin Feeley, Chief Financial Officer will host a conference call to discuss financial and operating results at 4:30 p.m. Eastern Time.

GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023

STAMFORD, Conn., April 03, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that Devin K. Schaffer has been appointed General Counsel, effective April 24, 2023. As a member of the executive leadership team, Devin will report directly to Katherine Stueland, President and CEO, and will be responsible for all legal, compliance, and regulatory activities for GeneDx.

GeneDx Appoints Devin K. Schaffer, J.D.

GeneDx changed its name from Sema4 in January. The company focuses on genetic testing to better inform healthcare decisions.

Why Shares of GeneDx Dropped Wednesday

STAMFORD, Conn., March 20, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp (GeneDx) (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it is continuing to support whole genome sequencing (WGS) and interpretation services for the GUARDIAN (Genomic Uniform-screening Against Rare Diseases In All Newborns) study, a research study recently launched by Columbia University using WGS to screen 100,000 newborns for more than 250 genetic conditions not currently included in standard newborn screening. Initial data from this study were presented at the ACMG Annual Meeting during the R. Rodney Howell Symposium, Setting the Stage for Genomic Sequencing of All Newborns, on Saturday, March 18, 2023.

GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”

Archer Aviation

Faraday Future Intelligent Electric

First Republic

Mullen Automotive

Nuvation Bio

Prelude Therapeutics

Generally, I dislike writing about the worst stocks to buy now (or similar themes) because it invariably offends members of the internet defense league. It's not the greatest experience to receive a flood of messages from people defending the honor of corporations who could care less about them.

The 7 Worst Stocks to Buy Now

GeneDx Holdings Corp. (NASDAQ:WGS ) Q4 2022 Earnings Conference Call March 14, 2023 4:30 PM ET Company Participants Tricia Truehart - Head IR Katherine Stueland - CEO Kevin Feeley - CFO Conference Call Participants Brandon Couillard - Jefferies Matthew Sykes - Goldman Sachs Vidyun Bais - BTIG Joseph Flanagan - Cowen Operator Thank you for standing by, and welcome to GeneDx' Fourth Quarter 2022 Earnings Conference Call. [Operator Instructions] I would now like to hand the call over to Head of Investor Relations, Tricia Truehart.

GeneDx Holdings Corp. (WGS) Q4 2022 Earnings Call Transcript

New research released at ACMG Annual Clinical Genetics Meeting reiterates the superiority of exome sequencing's role in shortening the diagnostic odyssey New research released at ACMG Annual Clinical Genetics Meeting reiterates the superiority of exome sequencing's role in shortening the diagnostic odyssey

GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray

Financial results are in line with previously announced preliminary 2022 results; Reiterating 2023 guidance, including total revenue of $205-220 million

GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

STAMFORD, Conn., March 01, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate at the Cowen 43rd Annual Healthcare Conference in Boston, MA. Katherine Stueland, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, March 7, 2023, at 2:50 p.m. ET.

GeneDx to Participate in the Cowen 43rd Annual Healthcare Conference

Nuburu Inc

Eos Energy Enterprises

Lucira Health

Protalix Biotherapeutics

Troika Media Group

Cheap penny stocks to watch before next week. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 7 Under $5 To Watch Before Next Week

Research illustrates company's progress in working to end the diagnostic odyssey and includes data with implications for how care is delivered to patients beginning at birth Research illustrates company's progress in working to end the diagnostic odyssey and includes data with implications for how care is delivered to patients beginning at birth

GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting

STAMFORD, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the fourth quarter and full year of 2022 after the market closes on Tuesday, March 14, 2023. On the same day, Katherine Stueland, Chief Executive Officer of GeneDx, and Kevin Feeley, Chief Financial Officer of GeneDx, will host a conference call to discuss financial and operating results at 4:30 p.m. Eastern Time.

GeneDx to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14th, 2023

Research published in Nature Genetics underscores the role of genetic insights in the drug discovery and development process Research published in Nature Genetics underscores the role of genetic insights in the drug discovery and development process

GeneDx Rare Disease Data Demonstrates Utility in Drug Candidate Identification for Common Diseases

Boxlight

Grove Collaborative Holdings

Imperial Petroleum

IronNet

Spectrum Pharma

VIQ Solutions

Virax Biolabs Group Ltd

Wearable Devices Ltd

Penny stocks under $1 to watch this month. The post 10 Top Penny Stocks Under $1 To Watch For February 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks Under $1 To Watch For February 2023

Iveda Solutions Inc

$1 penny stocks to watch right now. The post 7 Hot Penny Stocks Under $1 To Watch For February 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Hot Penny Stocks Under $1 To Watch For February 2023

Genetic Technologies

Gracell Biotechnologies

PaxMedica Inc

Penny stocks with news to watch this week. The post Penny Stocks To Buy: 4 To Watch With Big News In February appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy: 4 To Watch With Big News In February

STAMFORD, Conn., Jan. 31, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS) today announced the closing of its previously announced underwritten public offering of shares of its Class A common stock (the “Underwritten Offering”) and concurrent registered direct offering of shares of its Class A common stock (the “Direct Offering” and, together with the Underwritten Offering, the “Offerings”). The total gross proceeds are expected to be approximately $150 million, including proceeds from the issuance of the additional shares in the Direct Offering described below.

News for GeneDx Holdings Corp Stock (WGS)